Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.

BMC Cancer · 2025 · PMC12382151 · PMID 40866909

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in patients aged ≥ 75 years, the HR indicated a trend toward benefit but did not reach statistical significance (HR: 0.593; 95% CI, 0.221–1.588) (Additional File Fig. 2B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.